Klaich G M, Kanter P M
James T Grace Jr Cancer Drug Center, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Anticancer Drugs. 1995 Feb;6(1):45-52. doi: 10.1097/00001813-199502000-00005.
A monoclonal antibody (A7) was produced which recognizes an oncofetal antigen expressed on glioblastoma multiforme cells, fetal brain, fetal kidney, but not adult tissues. Radioimmunoprecipitates of Zwittergent 3-14 solubilized glioblastoma cells identified a single band at 138 kDa on 8% polyacrylamide sodium dodecylsulfate gels. Distribution studies of A7 in mice demonstrated a tri-phasic serum clearance of t1/2 alpha = 2.1 h, t1/2 beta = 16.7 h and t1/2 gamma = 151.1 h. Tumor localization studies using the U-87 MG xenograft demonstrated the ability of A7 to localize with a tumor:blood ratio of 1.294 +/- 0.094 as compared with 0.293 +/- 0.051 for control antibody AC. A7 does not damage cell membranes and is not internalized when bound to reactive tumor cells.
产生了一种单克隆抗体(A7),它能识别在多形性胶质母细胞瘤细胞、胎儿脑、胎儿肾中表达但不在成人组织中表达的一种癌胚抗原。用两性离子去污剂Zwittergent 3-14溶解的胶质母细胞瘤细胞的放射免疫沉淀物在8%聚丙烯酰胺十二烷基硫酸钠凝胶上鉴定出一条138 kDa的单带。A7在小鼠体内的分布研究表明其血清清除呈三相,t1/2α = 2.1小时,t1/2β = 16.7小时,t1/2γ = 151.1小时。使用U-87 MG异种移植瘤进行的肿瘤定位研究表明,A7能够定位到肿瘤部位,肿瘤与血液的比率为1.294±0.094,而对照抗体AC为0.293±0.051。A7不损伤细胞膜,与反应性肿瘤细胞结合时不会被内化。